Skip to main content

Advertisement

Table 1 Clinical characteristics of the patients with de novo Ph+ALL for in vitro and in vivo study

From: Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL

Case no. Age/sex WBC (×10E + 9/L) % CD34+ in blasts % CD34+CD38 CD58 in blasts BCR–ABL (P190/P210) Cytogenetics Outcome
1 F/23 26.3 90.5 5.6 P210 46, XX, t(9;22) [20] CCR
2 M/46 86.5 82.3 12.2 P210 46, XY, t(9;22) [20] Relapsed
3 M/40 65.3 86.5 8.6 P190 46, XY, t(9;22) [20] Relapsed
4 M/32 56.6 78.5 10.2 P190 46, XY, t(9;22) [20] CCR
5 F/50 167.3 98.6 11.6 P190 46, XX, t(9;22) [20] Relapsed
6 M/22 78.2 92.3 9.8 P190 46, XY, t(9;22) [20] Relapsed
  1. F, female; M, male; CCR, continuous complete remission